Aurobindo Pharma Limited — JV/Acquisition, 30-07-2025: Acquisition

Aurobindo Pharma is streamlining its biologics operations, acquiring 100% of its step-down subsidiary, CuraTeQ Biologics s.r.o. (Czech Republic), for EUR 3 million (approx. INR 30.3 Cr). This internal restructuring aims to vertically integrate the biologics/biosimilars business under CuraTeQ Biologics B.V. Since this is a reorganization between wholly-owned entities, there is no material financial impact on Aurobindo Pharma on a consolidated basis. CuraTeQ SRO currently shows no turnover, indicating this move is strategic for future segment consolidation.